Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment

System xc− in microglia is a novel therapeutic target for post-septic neurological and psychiatric illness

(2019) Yoshinori Kitagawa et al.   Scientific Reports

Targeting glutamate signalling in depression: progress and prospects

(2017) James W. Murrough et al.   NATURE REVIEWS DRUG DISCOVERY

Overexpression of EphB2 in hippocampus rescues impaired NMDA receptors trafficking and cognitive dysfunction in Alzheimer model

(2017) Rui Hu et al.   Cell Death & Disease

Emerging Synaptic Molecules as Candidates in the Etiology of Neurological Disorders

(2017) Viviana I. Torres et al.   NEURAL PLASTICITY

Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial

(2017) Chieh-Hsin Lin et al.   BIOLOGICAL PSYCHIATRY

N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington’s disease

(2016) Dean J. Wright et al.   HUMAN MOLECULAR GENETICS

Decreased mRNA expression for the two subunits of system xc−, SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: Evidence in support of the hypo-glutamatergic hypothesis of schizophrenia

(2016) Chieh-Hsin Lin et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Main path and byways: non-vesicular glutamate release by system xc−as an important modifier of glutamatergic neurotransmission

(2015) Ann Massie et al.   JOURNAL OF NEUROCHEMISTRY

Impaired Attention and Synaptic Senescence of the Prefrontal Cortex Involves Redox Regulation of NMDA Receptors

(2015) M. Guidi et al.   JOURNAL OF NEUROSCIENCE

d-Aspartate: An endogenous NMDA receptor agonist enriched in the developing brain with potential involvement in schizophrenia

(2015) Francesco Errico et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Glutamate and dopamine in schizophrenia: An update for the 21st century

(2015) Oliver Howes et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Emerging roles of system antiporter and its inhibition in CNS disorders

(2015) Dhaval Patel et al.   MOLECULAR MEMBRANE BIOLOGY

Different Paths to Core Pathology: The Equifinal Model of the Schizophrenia Syndrome

(2015) Isobel W. Green et al.   SCHIZOPHRENIA BULLETIN

Glutamatergic agents for schizophrenia: current evidence and perspectives

(2015) Mathias Zink et al.   Expert Review of Clinical Pharmacology

Cinnamon and Its Metabolite Sodium Benzoate Attenuate the Activation of p21rac and Protect Memory and Learning in an Animal Model of Alzheimer’s Disease

(2015) Khushbu K. Modi et al.   PLoS One

NMDA Neurotransmission Dysfunction in Mild Cognitive Impairment and Alzheimer’s Disease

(2014) Chieh-Hsin Lin et al.   CURRENT PHARMACEUTICAL DESIGN

NMDA Pathology and Treatment of Schizophrenia

(2014) Huey-Jen Chang et al.   CURRENT PHARMACEUTICAL DESIGN

Accelerated Aging in Schizophrenia Patients: The Potential Role of Oxidative Stress

(2014)   Aging and Disease

The DAO Gene Is Associated with Schizophrenia and Interacts with Other Genes in the Taiwan Han Chinese Population

(2013) Hsin-Chou Yang et al.   PLoS One

The Cystine/Glutamate Antiporter System xc− in Health and Disease: From Molecular Mechanisms to Novel Therapeutic Opportunities

(2012) Jan Lewerenz et al.   ANTIOXIDANTS & REDOX SIGNALING

NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease

(2012) Yu-Jhen Huang et al.   Current Neuropharmacology

System xc- cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS

(2011) Richard J Bridges et al.   BRITISH JOURNAL OF PHARMACOLOGY

Glutamate signaling in the pathophysiology and therapy of schizophrenia

(2011) Chieh-Hsin Lin et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

D-Amino acid oxidase controls motoneuron degeneration through D-serine

(2011) J. Sasabe et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Translating Glutamate: From Pathophysiology to Treatment

(2011) D. C. Javitt et al.   Science Translational Medicine

Genetic Association Studies of Antioxidant Pathway Genes and Schizophrenia

(2010) Kodavali V. Chowdari et al.   ANTIOXIDANTS & REDOX SIGNALING

System xc−and Thioredoxin Reductase 1 Cooperatively Rescue Glutathione Deficiency

(2010) Pankaj Kumar Mandal et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

High-dose glycine impairs the prepulse inhibition measure of sensorimotor gating in humans

(2010) BV O’Neill et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Co-Administration of a D-Amino Acid Oxidase Inhibitor Potentiates the Efficacy of D-Serine in Attenuating Prepulse Inhibition Deficits After Administration of Dizocilpine

(2009) Kenji Hashimoto et al.   BIOLOGICAL PSYCHIATRY

Redox dysregulation, neurodevelopment, and schizophrenia

(2009) Kim Q Do et al.   CURRENT OPINION IN NEUROBIOLOGY

Association analysis of glycine- and serine-related genes in a Japanese population of patients with schizophrenia

(2009) Tohru Ohnuma et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

The Role of Cystine-Glutamate Exchange in Nicotine Dependence in Rats and Humans

(2008) Lori A. Knackstedt et al.   BIOLOGICAL PSYCHIATRY

Time-dependent changes in striatal xCT protein expression in hemi-Parkinson rats

(2008) Ann Massie et al.   NEUROREPORT

Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia

(2008) P BURNET et al.   SCHIZOPHRENIA RESEARCH